The pan-JAK inhibitor CP-690550 [85], the JAK1/3 inhibitor tofacitinib [87] and the selective STAT3 inhibitor WP1066 [86] could inhibit the proliferation and induce apoptosis in several NKTCL cell lines. Here, JAK1 is linked to extranodal nasal NK/T cell lymphoma.